Historical Valuation
Innate Pharma SA (IPHA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.65 is considered Undervalued compared with the five-year average of -2.65. The fair price of Innate Pharma SA (IPHA) is between 857.07 to 858.22 according to relative valuation methord. Compared to the current price of 1.76 USD , Innate Pharma SA is Undervalued By 99.79%.
Relative Value
Fair Zone
857.07-858.22
Current Price：1.76
99.79%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Innate Pharma SA (IPHA) has a current Price-to-Book (P/B) ratio of 27.83. Compared to its 3-year average P/B ratio of 9.65 , the current P/B ratio is approximately 188.43% higher. Relative to its 5-year average P/B ratio of 6.67, the current P/B ratio is about 317.31% higher. Innate Pharma SA (IPHA) has a Forward Free Cash Flow (FCF) yield of approximately -27.70%. Compared to its 3-year average FCF yield of -13.90%, the current FCF yield is approximately 99.32% lower. Relative to its 5-year average FCF yield of -14.16% , the current FCF yield is about 95.56% lower.
P/B
Median3y
9.65
Median5y
6.67
FCF Yield
Median3y
-13.90
Median5y
-14.16
Competitors Valuation Multiple
AI Analysis for IPHA
The average P/S ratio for IPHA competitors is 7711.28, providing a benchmark for relative valuation. Innate Pharma SA Corp (IPHA.O) exhibits a P/S ratio of 3.65, which is -99.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IPHA
1Y
3Y
5Y
Market capitalization of IPHA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IPHA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IPHA currently overvalued or undervalued?
Innate Pharma SA (IPHA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.65 is considered Undervalued compared with the five-year average of -2.65. The fair price of Innate Pharma SA (IPHA) is between 857.07 to 858.22 according to relative valuation methord. Compared to the current price of 1.76 USD , Innate Pharma SA is Undervalued By 99.79% .
What is Innate Pharma SA (IPHA) fair value?
IPHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Innate Pharma SA (IPHA) is between 857.07 to 858.22 according to relative valuation methord.
How does IPHA's valuation metrics compare to the industry average?
The average P/S ratio for IPHA's competitors is 7711.28, providing a benchmark for relative valuation. Innate Pharma SA Corp (IPHA) exhibits a P/S ratio of 3.65, which is -99.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Innate Pharma SA (IPHA) as of Jan 10 2026?
As of Jan 10 2026, Innate Pharma SA (IPHA) has a P/B ratio of 27.83. This indicates that the market values IPHA at 27.83 times its book value.
What is the current FCF Yield for Innate Pharma SA (IPHA) as of Jan 10 2026?
As of Jan 10 2026, Innate Pharma SA (IPHA) has a FCF Yield of -27.70%. This means that for every dollar of Innate Pharma SA’s market capitalization, the company generates -27.70 cents in free cash flow.
What is the current Forward P/E ratio for Innate Pharma SA (IPHA) as of Jan 10 2026?
As of Jan 10 2026, Innate Pharma SA (IPHA) has a Forward P/E ratio of -3.58. This means the market is willing to pay $-3.58 for every dollar of Innate Pharma SA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Innate Pharma SA (IPHA) as of Jan 10 2026?
As of Jan 10 2026, Innate Pharma SA (IPHA) has a Forward P/S ratio of 3.65. This means the market is valuing IPHA at $3.65 for every dollar of expected revenue over the next 12 months.